信邦制药(002390) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥1,518,785,929.13, a decrease of 3.06% compared to the same period last year[1]. - Net profit attributable to shareholders was ¥61,710,285.59, down 31.85% year-on-year[1]. - The net profit after deducting non-recurring gains and losses was ¥60,385,804.29, reflecting a decline of 34.34% compared to the previous year[1]. - Total operating revenue for Q3 2024 was CNY 4,565,355,757.09, a decrease of 5.35% from CNY 4,823,207,646.87 in Q3 2023[14]. - Net profit for Q3 2024 was CNY 232,737,545.03, down 23.3% from CNY 303,445,405.77 in Q3 2023[15]. - Basic earnings per share for Q3 2024 were CNY 0.0927, compared to CNY 0.1270 in Q3 2023, a decrease of 26.9%[15]. Assets and Liabilities - The total assets at the end of the reporting period were ¥8,896,668,585.81, a decrease of 3.77% from the end of the previous year[1]. - As of September 30, 2024, total assets amounted to RMB 8,896,668,585.81, a decrease from RMB 9,244,971,150.19 at the beginning of the period[12]. - Current assets decreased from RMB 5,411,532,415.23 to RMB 5,143,487,009.54, primarily due to a reduction in cash and inventory[11]. - The company reported a decrease in total liabilities from RMB 2,058,568,934.81 to RMB 1,758,880,279.46, suggesting improved financial health[12]. - The total liabilities decreased to CNY 1,799,699,445.74 from CNY 2,102,884,529.82, indicating a reduction of 14.4%[14]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥429,846,275.78, down 40.97% compared to the same period last year[4]. - Cash flow from operating activities was CNY 429,846,275.78, a decrease of 41% compared to CNY 728,135,122.51 in Q3 2023[16]. - The net cash flow from investing activities was -¥92,141,883.78, a decrease from -¥44,793,241.06 in the previous year, indicating a significant increase in investment outflows[17]. - Cash inflow from financing activities totaled ¥658,293,204.46, down from ¥1,170,630,222.41 year-over-year, reflecting a reduction in financing activities[17]. - The total cash and cash equivalents at the end of the period stood at ¥708,271,054.89, down from ¥979,774,677.45 at the end of the previous year[17]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 68,434[5]. - The largest shareholder, Guizhou Jinyu Industrial Investment Partnership, held 18.52% of the shares, totaling 360,000,000 shares[5]. - The company completed a share repurchase plan, acquiring 47,445,540 shares, representing 2.44% of the total share capital, with a total transaction amount of RMB 199,908,800[8]. - The company plans to distribute a cash dividend of RMB 0.30 per 10 shares, totaling RMB 56,892,189.84 for the first half of 2024[9]. Research and Development - Research and development expenses increased by 86.83% year-on-year, amounting to ¥3,824,833.20[3]. - R&D expenses increased to CNY 3,824,833.20, up 86.7% from CNY 2,047,197.90 in the same period last year[14]. Other Income and Expenses - The company recorded a decrease in other income by 33.48%, amounting to ¥3,296,082.51, due to a reduction in government subsidies received[3]. - The company reported a decrease in sales expenses to CNY 229,262,839.63 from CNY 254,852,297.29, a reduction of 10%[14]. - Deferred income decreased to CNY 20,829,918.25 from CNY 22,039,139.27, reflecting a decline of 5.5%[14].